Comparison of Underdilated Versus Standard TIPS in Preventing Variceal Rebleeding in Patients With Cirrhosis

Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18-75
SponsorAir Force Military Medical University, China

About this trial

Transjugular intrahepatic portosystemic shunt (TIPS) is a key therapeutic intervention for complications of portal hypertension. However, the risk of post-procedural hepatic encephalopathy (HE) limits its broader clinical application. In the management of gastroesophageal variceal bleeding, the primary goal of TIPS is to reduce the portosystemic pressure gradient (PPG) to less than 12 mmHg (16 cmH₂O), which defines the standard TIPS procedure. The investigators hypothesize that, in patients undergoing TIPS for the prevention of variceal rebleeding, stent underdilation using a 6-mm balloon (underdilated TIPS) will not increase the risk of rebleeding but may reduce the incidence of overt HE and attenuate liver injury. To test this hypothesis, the investigators have designed a prospective, multicenter, randomized controlled trial.

Eligibility criteria

Qualifiers

High-risk acute esophageal or type 1 gastroesophageal variceal bleeding, including: Child-Pugh grade B with a score > 7 and endoscopic evidence of active bleeding; Child-Pugh grade C with a score < 14.

Hepatic venous pressure gradient (HVPG) > 20 mmHg during bleeding.

Early rebleeding within 5 days.

Bleeding uncontrolled despite pharmacological and endoscopic therapy. 4. History of esophageal or gastric variceal bleeding with failure of standard first-line treatment [endoscopy combined with non-selective beta-blockers (NSBB)]; or first hemorrhage accompanied by grade 2 ascites and/or portal vein thrombosis; GOV2 or IGV1 gastric variceal bleeding; ectopic variceal bleeding; or bleeding from refractory portal hypertensive gastropathy.

Disqualifiers

Budd-Chiari syndrome or other causes of non-cirrhotic portal hypertension.

Current or prior malignancy, including hepatocellular carcinoma or malignancies of other organs.

Complete thrombosis of the main portal vein.

Severe psychiatric or neurologic disorders (e.g., uncontrolled epilepsy, dementia).

Trial design

Treatments tested in this trial

  • Underdilated TIPS
  • Standard TIPS

Treatment groups

648 Participants
are divided into 2 treatment groups

Sponsors and collaborators

Air Force Military Medical University, China

Lead sponsor

West China Hospital

Collaborator

The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School

Collaborator

Daping Hospital of Army Medical University

Collaborator

General Hospital of Ningxia Medical University

Collaborator